The abstract is read at the publisher; the summary is JClub's.
Younger age groups show consistently higher durability of Shingrix-induced gE-specific CD4+ T cell and anti-gE antibody responses than older groups, persisting across simulated contraction and persistence phases.
- Why it matters: Long-term protection and vaccine scheduling depend on how immunity wanes over time, yet immunosenescence may change both the magnitude and persistence of vaccine responses.
- What they did: The study built a semi-mechanistic model with virtual populations to capture inter-individual variability in peak levels and waning, then quantified age effects using a time-varying immune advantage metric.
- The result: Simulations suggest booster doses given between 6 and 12 months after the second dose may mitigate age-related differences in antibody dynamics in older age groups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.